Company News

In May 2024, bioMérieux entered into a strategic partnership with AnaBioTec, an analytical service provider for pharmaceutical, biopharmaceutical and cell-based drugs, from early to late phases of development. Both companies intend to advance and transform Mycoplasma testing for the biopharmaceutical and Cell & Gene Therapy (CGT) industries, in Europe.

bioMérieux inaugurated its new Rodolphe Mérieux Campus on May 31, in Bagno a Ripoli, Italy, in the presence of Alain Mérieux, Chairman of Institut Mérieux, and Pierre Boulud, Chief Executive Officer of bioMérieux. The site comprises of a new R&D center focusing on the fight against Antimicrobial Resistance. This is the result of an investment of €9 million.

bioMérieux, a world leader in the field of in vitro diagnostics, has received the 2024 Business of the Year Award, presented by the Utah Governor’s Office of Economic Opportunity at One Utah Summit April 11-12, in Salt Lake City.

bioMérieux has entered into a strategic research collaboration with the US Food and Drug Administration (FDA), Center for Food Safety and Applied Nutrition (CFSAN), Offices of Applied Research and Safety Assessment (OARSA) and Regulatory Science (ORS) to develop tools to combat food-borne pathogens.